Manulife (Manufacturers Life Insurance)’s Design Therapeutics DSGN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,955	Closed	-$40.3K	–	2924
2025 Q2	$40.3K	Sell	11,955 -1,002	-8%	-$3.75K	﹤0.01%	2900
2025 Q1	$50K	Sell	12,957 -113	-0.9%	-$539	﹤0.01%	2832
2024 Q4	$80.6K	Sell	13,070 -151	-1%	-$874	﹤0.01%	2867
2024 Q3	$71.1K	Buy	+13,221	New	+$62.2K	﹤0.01%	2941
2023 Q3	–	Sell	-15,173	Closed	-$95.6K	–	2986
2023 Q2	$95.6K	Buy	15,173 +1,546	+11%	+$9.46K	﹤0.01%	2863
2023 Q1	$78.6K	Hold	13,627	–	–	﹤0.01%	2791
2022 Q4	$140K	Sell	13,627 -28,658	-68%	-$388K	﹤0.01%	2704
2022 Q3	$709K	Sell	42,285 -343	-0.8%	-$6.83K	﹤0.01%	1764
2022 Q2	$597K	Sell	42,628 -6,851	-14%	-$92.5K	﹤0.01%	1927
2022 Q1	$794K	Buy	49,479 +36,353	+277%	+$557K	﹤0.01%	1889
2021 Q4	$280	Buy	+13,126	New	+$225K	﹤0.01%	2659

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s DSGN Position: Q3 2025 in Review

Manulife (Manufacturers Life Insurance) sold out of Design Therapeutics (DSGN) in Q3 2025, closing a stake of 11,955 shares — an estimated $40.3K sold.

Manulife (Manufacturers Life Insurance) first reported a position in DSGN in Q4 2021 and held it in 11 quarters. The position peaked at $794K in Q1 2022. 95 funds tracked by Wall St. Rank hold DSGN as of Q3 2025.

Manulife (Manufacturers Life Insurance) reported no remaining Design Therapeutics position as of Q3 2025 after selling out during the quarter.
Manulife (Manufacturers Life Insurance) sold 11,955 Design Therapeutics shares in Q3 2025, an estimated $40.3K.
Manulife (Manufacturers Life Insurance) first reported a position in Design Therapeutics in Q4 2021 and held it in 11 quarters.
Manulife (Manufacturers Life Insurance)'s Design Therapeutics position peaked at $794K in Q1 2022.
95 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2025.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q3 2025, filed 14 Nov 2025.